A61K 38/2013
Il-2
Official title: {il-2}
A61K38/2013 (Il-2) appears on 947 US grants and 1,675 published applications in this corpus.
Search patents in A61K- Granted patents
- 947
- Published applications
- 1,675
- Assignees
- 716
- Inventors
- 2,786
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 4 | 0 |
| 1989 | 8 | 0 |
| 1990 | 5 | 0 |
| 1991 | 5 | 0 |
| 1992 | 10 | 0 |
| 1993 | 9 | 0 |
| 1994 | 10 | 0 |
| 1995 | 5 | 0 |
| 1996 | 8 | 0 |
| 1997 | 11 | 0 |
| 1998 | 17 | 0 |
| 1999 | 13 | 0 |
| 2000 | 15 | 0 |
| 2001 | 11 | 6 |
| 2002 | 12 | 19 |
| 2003 | 12 | 35 |
| 2004 | 7 | 38 |
| 2005 | 8 | 38 |
| 2006 | 10 | 40 |
| 2007 | 8 | 54 |
| 2008 | 16 | 27 |
| 2009 | 6 | 31 |
| 2010 | 18 | 46 |
| 2011 | 14 | 44 |
| 2012 | 17 | 50 |
| 2013 | 21 | 42 |
| 2014 | 34 | 51 |
| 2015 | 35 | 65 |
| 2016 | 37 | 50 |
| 2017 | 51 | 61 |
| 2018 | 34 | 81 |
| 2019 | 57 | 94 |
| 2020 | 49 | 91 |
| 2021 | 68 | 138 |
| 2022 | 69 | 133 |
| 2023 | 55 | 117 |
| 2024 | 64 | 147 |
| 2025 | 60 | 103 |
| 2026 | 49 | 74 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biased IL2 muteins methods and compositions15 Sep 2026US 12,734,215 B2Synthekine, Inc.
- Histamine receptor agonists for cancer therapy in cancer patients unresponsive to cancer immunotherapy and with elevated myeloid derived suppressor cells25 Aug 2026US 12,714,695 B2TSP Therapeutics Inc.
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Engineered adenovirus vectors and uses thereof18 Aug 2026US 12,709,761 B2
- Compositions and methods for treatment of headache disorders and neuropathic pain11 Aug 2026US 12,702,697 B2Washington University
- Novel conjugate of immune-stimulating il-2 analog and preparation method thereof8 Oct 2026US 2026/0306646 A1Hanmi Pharm. Co., Ltd.
- Targeted lipid nanoparticles for treating central nervous system injuries8 Oct 2026US 2026/0306665 A1Wisconsin Alumni Research Foundation
- Histamine receptor agonists for cancer therapy in cancer patients unresponsive to cancer immunotherapy and with elevated myeloid derived suppressor cells1 Oct 2026US 2026/0294873 A1TSP Therapeutics Inc.
- Oncolytic virus therapy1 Oct 2026US 2026/0294987 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same1 Oct 2026US 2026/0295010 A1
Most cited
By later US patents
- Solubilization of proteins for pharmaceutical compositions using polymer conjugation538US 4,766,106 ACetus Corporation · 1988
- Interleukin-2 muteins and polymer conjugation thereof444US 5,206,344 ACetus Oncology Corporation · 1993
- Adoptive immunotherapy as a treatment modality in humans344US 4,690,915 AThe United States of America as represented by the Department of Health and Human Services · 1987
- Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers310US 5,702,717 AMacroMed, Inc. · 1997
- Lineage-directed induction of human mesenchymal stem cell differentiation264US 5,736,396 ACase Western Reserve University · 1998